AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17601900 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out HIV testing strategy
Number of subjects: 1233
Study 17607331 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 513
Study 17607331 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg/day
Number of subjects: 513
Study 17607331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 513
Study 17609424 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic modification of antigen-presenting cells (APCs) to augment LMP2 expression.
Number of subjects: 16
Study 17620582 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17621382 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 240
Study 17624842 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk from HIV-infected women
Number of subjects: 725
Study 17624842 — intervention group
Group type: COMPARATOR
Intervention: Breast milk from HIV-uninfected women
Number of subjects: 725
Study 17624842 — intervention group
Group type: COMPARATOR
Intervention: Breast milk from HIV-exposed uninfected women
Number of subjects: 725
Study 17624842 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of breast-feeding
Number of subjects: 725
Study 17626713 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10, 20, 40, 80 mg/day)
Number of subjects: 610
Study 17634466 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF antibodies
Number of subjects: 0
Study 17634466 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 17635942 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1000 mg at 10- to 14-wk intervals
Number of subjects: 66
Study 17635942 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 66
Study 17637939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 17643576 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 48612
Study 17643576 — intervention group
Group type: COMPARATOR
Intervention: No Diabetes Mellitus (nondiabetic patients)
Number of subjects: 48612
Study 17646603 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of complete discharge instructions
Number of subjects: 48612
Study 17646603 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking-cessation counseling
Number of subjects: 48612
Study 17646603 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular function assessment
Number of subjects: 48612
Study 17646603 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors prescribed at discharge
Number of subjects: 48612
Study 17646603 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of preprinted admission order sets and/or discharge checklists
Number of subjects: 48612
Study 17646603 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean length of stay
Number of subjects: 48612
Study 17646603 — intervention group
Group type: EXPERIMENTAL
Intervention: Trends for reduction of in-hospital mortality, postdischarge death, and combined postdischarge death and rehospitalization
Number of subjects: 48612
Study 17647221 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy (n = 64) with educational materials, 90 minutes once a week for a minimum of 1 year.
Number of subjects: 125
Study 17647221 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 61) with only educational materials for a minimum of 1 year.
Number of subjects: 125
Study 17647221 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy for ER-negative participants.
Number of subjects: 125
Study 17647221 — intervention group
Group type: COMPARATOR
Intervention: Control for ER-negative participants.
Number of subjects: 125
Study 17647221 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy for ER-positive participants.
Number of subjects: 125
Study 17647221 — intervention group
Group type: COMPARATOR
Intervention: Control for ER-positive participants.
Number of subjects: 125
Study 17650319 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human prolactin (r-hPRL)
Number of subjects: 21
Study 17656603 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year obesity intervention program
Number of subjects: 133
Study 17656603 — intervention group
Group type: COMPARATOR
Intervention: Obese children
Number of subjects: 133
Study 17656603 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in PTH and 25-OH Vit D
Number of subjects: 133
Study 17659962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection (1.25 mg/0.05 ml)
Number of subjects: 3
Study 17662149 — intervention group
Group type: EXPERIMENTAL
Intervention: Active RA patients
Number of subjects: 17
Study 17666616 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor regimen
Number of subjects: 158
Study 17666616 — intervention group
Group type: COMPARATOR
Intervention: No protease inhibitor regimen
Number of subjects: 158
Study 17666616 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 158
Study 17666616 — intervention group
Group type: EXPERIMENTAL
Intervention: High triglycerides group
Number of subjects: 158
Study 17673691 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic patients
Number of subjects: 90
Study 17673691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonseptic patients with OF
Number of subjects: 90
Study 17673691 — intervention group
Group type: COMPARATOR
Intervention: Both patient groups (septic and nonseptic)
Number of subjects: 90
Study 17679662 — intervention group
Group type: EXPERIMENTAL
Intervention: McDonald's branded foods and beverages
Number of subjects: 63
Study 17679662 — intervention group
Group type: COMPARATOR
Intervention: Unbranded foods and beverages
Number of subjects: 63
Study 17679671 — intervention group
Group type: EXPERIMENTAL
Intervention: Weill Cornell LINCL scale
Number of subjects: 18
Study 17679671 — intervention group
Group type: COMPARATOR
Intervention: Modified Hamburg LINCL scale
Number of subjects: 18
Study 17679671 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measurements
Number of subjects: 18
Study 17679671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical MRS N-acetyl-aspartate content, MRI ventricular, gray matter and white matter volume, and cortical apparent diffusion coefficient
Number of subjects: 18
Study 17679729 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine alone (20 mg/m(2)/d intravenously for 10 days)
Number of subjects: 25
Study 17679729 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine plus valproic acid (VA) (at OBD, days 1 through 10, with dose-escalating VA days 5 through 21)
Number of subjects: 25
Study 17679729 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 17682000 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI)
Number of subjects: 62
Study 17682000 — intervention group
Group type: COMPARATOR
Intervention: White light
Number of subjects: 62
Study 17684047 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard replacement therapy for adrenal insufficiency
Number of subjects: 256
Study 17686450 — intervention group
Group type: EXPERIMENTAL
Intervention: One-drug group (prostaglandin analogs)
Number of subjects: 62
Study 17686450 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-drug group (prostaglandin analogs plus adjunctive medication)
Number of subjects: 62
Study 17686450 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor antagonists (part of two-drug group)
Number of subjects: 62
Study 17686822 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with bevacizumab and chemotherapy
Number of subjects: 1745
Study 17686822 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1745
Study 17686822 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline or on-study aspirin use in bevacizumab-treated patients
Number of subjects: 1745
Study 17686822 — intervention group
Group type: COMPARATOR
Intervention: Baseline or on-study aspirin use in control subjects
Number of subjects: 1745
Study 17687130 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m²) administered as four weekly infusions
Number of subjects: 21
Study 17694552 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin-alpha at a dose of 200 microg every 2 weeks
Number of subjects: 2401
Study 17698748 — intervention group
Group type: EXPERIMENTAL
Intervention: hsUHR-OCT imaging
Number of subjects: 8
Study 17698748 — intervention group
Group type: COMPARATOR
Intervention: Conventional slitlamp biomicroscopy
Number of subjects: 8
Study 17699416 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 20,000 IU subcutaneously every 2 weeks
Number of subjects: 67
Study 17700015 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVH with regional citrate anticoagulation (RCA)
Number of subjects: 51
Study 17700015 — intervention group
Group type: COMPARATOR
Intervention: CVVH without regional citrate anticoagulation (anticoagulant-free predilution CVVH)
Number of subjects: 51
Study 17700015 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVH with RCA
Number of subjects: 51
Study 17700015 — intervention group
Group type: COMPARATOR
Intervention: CVVH with RCA and CVVH without RCA
Number of subjects: 51
Study 17704543 — intervention group
Group type: COMPARATOR
Intervention: Normal blood pressure (120-9/75-84 mm Hg)
Number of subjects: 39322
Study 17704543 — intervention group
Group type: EXPERIMENTAL
Intervention: High normal blood pressure (130-9/85-9 mm Hg)
Number of subjects: 39322
Study 17704543 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hypertension
Number of subjects: 39322
Study 17704543 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression to hypertension
Number of subjects: 39322
Study 17704543 — intervention group
Group type: EXPERIMENTAL
Intervention: High normal blood pressure who progressed to hypertension
Number of subjects: 39322
Study 17705950 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 829
Study 17705950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 829
Study 17707182 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure with preserved systolic function (PSF) (EF > or =40%)
Number of subjects: 21149
Study 17707182 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or beta-blocker
Number of subjects: 21149
Study 17709602 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (400 mg daily) dose de-escalation
Number of subjects: 5
Study 17709602 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinitiation of therapy at prior effective dose
Number of subjects: 5
Study 17709602 — intervention group
Group type: COMPARATOR
Intervention: Imatinib (300 to 400 mg daily)
Number of subjects: 5
Study 17709827 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab alone (cycle 1)
Number of subjects: 19
Study 17709827 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy (cycles 2-7)
Number of subjects: 19
Study 17713466 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 176
Study 17715389 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg orally twice daily
Number of subjects: 280
Study 17717136 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA), a histone deacetylase inhibitor, used as a chronic treatment for epileptic disorders.
Number of subjects: 0
Study 17717285 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible intensive insulin therapy
Number of subjects: 0
Study 17717285 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 0
Study 17718658 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Management (CM) plus primary care
Number of subjects: 419
Study 17723147 — intervention group
Group type: EXPERIMENTAL
Intervention: ORAL IMPACT (immunonutrient formula)
Number of subjects: 142
Study 17723147 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative follow-up for 12 weeks
Number of subjects: 142
Study 17725843 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg once a day for 12 weeks)
Number of subjects: 533
Study 17727882 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine treatment
Number of subjects: 0
Study 17761590 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (previously received)
Number of subjects: 15
Study 17761592 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-flow pump implantation
Number of subjects: 133
Study 17761710 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (182 mg for rapid acetylators, 83 mg for slow acetylators) and magnesium valproate (40 mg/kg) added to chemotherapy schedule.
Number of subjects: 17
Study 17761710 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine and magnesium valproate intervention.
Number of subjects: 17
Study 17761710 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (cisplatin, carboplatin, paclitaxel, vinorelbine, gemcitabine, pemetrexed, topotecan, doxorubicin, cyclophosphamide, anastrozole).
Number of subjects: 17
Study 17765429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpreserved intravitreal triamcinolone acetonide in prefilled syringes, injected intravitreally without topical antibiotics prior to injection.
Number of subjects: 839
Study 17767397 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblimersen in combination with dacarbazine
Number of subjects: 771
Study 17767397 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine alone
Number of subjects: 771
Study 17767471 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole treatment for 5 years (median)
Number of subjects: 63
Study 17784944 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial duplex scanning (TCD) of the substantia nigra
Number of subjects: 250
Study 17784944 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT scan of the brain
Number of subjects: 250
Study 17803825 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking with partial weight support via an overhead harness
Number of subjects: 130
Study 17803825 — intervention group
Group type: COMPARATOR
Intervention: Routine assisted overground walking
Number of subjects: 130
Study 17804683 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0
Study 17804777 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic needle tracking with CT and US guidance
Number of subjects: 19
Study 17804777 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion of tracked US with CT
Number of subjects: 19
Study 17804851 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17822557 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with HER2 ICD protein-containing dendritic cells (DC) administered intradermally/subcutaneously four times at 3 week intervals.
Number of subjects: 7
Study 17823147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 0
Study 17825712 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5FGF-4 (alferminogene tadenovec)
Number of subjects: 532
Study 17825712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 532
Study 17825841 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 600
Study 17825841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 17846226 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (20 mg/m(2)) plus interleukin-12 (IL-12; 300 ng/kg subcutaneously twice weekly) followed by 500 ng/kg subcutaneous IL-12 twice weekly for up to 3 years
Number of subjects: 36
Study 17854392 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year outpatient obesity intervention programme based on a high-carbohydrate, fat-reduced diet and increased physical activity
Number of subjects: 44
Study 17854392 — intervention group
Group type: COMPARATOR
Intervention: Obese children
Number of subjects: 44
Study 17854392 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with substantial weight loss
Number of subjects: 44
Study 17869664 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Point A (TPA)
Number of subjects: 11
Study 17869664 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated brachytherapy dose to APA
Number of subjects: 11
Study 17875804 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccine of PR1 and WT1 peptides in Montanide adjuvant with granulocyte-macrophage colony-stimulating factor
Number of subjects: 8
Study 17875804 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccine of PR1 and WT1 peptides
Number of subjects: 8
Study 17875973 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner syndrome (TS) women with ascending aortic diameters > 2.0 cm/m2 (aortic size index)
Number of subjects: 166
Study 17875973 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner syndrome (TS) women
Number of subjects: 166
Study 17875973 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner syndrome (TS) women with ascending aortic diameters of 3.7 to 4.8 cm and aortic size indices > 2.5 cm/m2
Number of subjects: 166
Study 17875973 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner syndrome (TS) women with aortic size index > 2.0 cm/m2
Number of subjects: 166
Study 17875973 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner syndrome (TS) women with aortic size index >= 2.5 cm/m2
Number of subjects: 166
Study 17876370 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical acetylcholine chloride
Number of subjects: 10
Study 17876370 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin
Number of subjects: 10
Study 17876370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17877652 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone
Number of subjects: 336
Study 17877830 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-component hospital-based staff communication protocol designed to improve interprofessional collaborative communication.
Number of subjects: 20
Study 17877830 — intervention group
Group type: COMPARATOR
Intervention: Usual communication practices (Control group).
Number of subjects: 20
Study 17885618 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 96
Study 17890470 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance oscillometry (IOS)
Number of subjects: 174
Study 17890470 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilation
Number of subjects: 174
Study 17892636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfasting LDLc
Number of subjects: 31
Study 17892636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfasting non-HDLc
Number of subjects: 31
Study 17892636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfasting LDLP
Number of subjects: 31
Study 17892636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfasting DLDLc
Number of subjects: 31
Study 17892636 — intervention group
Group type: COMPARATOR
Intervention: Fasting LDLc
Number of subjects: 31
Study 17892636 — intervention group
Group type: COMPARATOR
Intervention: Fasting DLDLc
Number of subjects: 31
Study 17892636 — intervention group
Group type: COMPARATOR
Intervention: Fasting non-HDLc
Number of subjects: 31
Study 17892636 — intervention group
Group type: COMPARATOR
Intervention: Fasting LDLP
Number of subjects: 31
Study 17893227 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral lenalidomide daily
Number of subjects: 214
Study 17893227 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lenalidomide on days 1 to 21 of a 28-day cycle
Number of subjects: 214
Study 17893227 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lenalidomide
Number of subjects: 214
Study 17896299 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-line gain in visual acuity of the better-seeing eye
Number of subjects: 828
Study 17896299 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-line loss in visual acuity of the better-seeing eye
Number of subjects: 828
Study 17896299 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with baseline NEI-VFQ scores > 59.8 and 2-line loss in visual acuity
Number of subjects: 828
Study 17896299 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with baseline NEI-VFQ scores ≤ 59.8 and 2-line loss in visual acuity
Number of subjects: 828
Study 17896299 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall NEI-VFQ score
Number of subjects: 828
Study 17896299 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual subscale scores
Number of subjects: 828
Study 17897454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPTi) with sulphadoxine-pyrimethamine (SP) administered 3 times alongside routine vaccinations.
Number of subjects: 0
Study 17897454 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 3 times alongside routine vaccinations.
Number of subjects: 0
Study 17897470 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nitric oxide releasing patches
Number of subjects: 100
Study 17897470 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 100
Study 17898351 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 100
Study 17898351 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 100
Study 17898351 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 100
Study 17903262 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (BTX-A) 10 units per Kg
Number of subjects: 150
Study 17903262 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 150
Study 17905796 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral GPi-DBS
Number of subjects: 10
Study 17906013 — intervention group
Group type: EXPERIMENTAL
Intervention: One-layer closure
Number of subjects: 30
Study 17906013 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-layer closure
Number of subjects: 30
Study 17906013 — intervention group
Group type: COMPARATOR
Intervention: Both one- and two-layer closure
Number of subjects: 30